In ₹ Crore except Per Share Latest Annual | GRANULES FY26 | AUROPHARMA FY26 | IPCALAB FY26 | AARTIDRUGS FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | 36.64× | 27.61× | 43.84× | ◆ 20.46× | 27.61× +33% | |
| P/B | 4.37× | ◆ 2.55× | 5.25× | 2.57× | 2.57× +70% | |
| EV/EBITDA | 19.13× | ◆ 14.10× | 25.10× | 14.74× | 14.74× +30% | |
| Market Cap | ₹22,215 Cr | ₹96,761 Cr | ₹50,032 Cr | ₹3,988 Cr | ₹50,032 Cr -56% | |
| Growth | ||||||
| Revenue CAGR 3Y | 5.95% | 10.63% | ◆ 15.60% | -1.89% | 10.63% -44% | |
| Revenue CAGR 5Y | 10.63% | 6.32% | ◆ 12.22% | 3.55% | 6.32% +68% | |
| Net Income CAGR 3Y | 4.82% | 22.03% | ◆ 35.20% | 5.43% | 22.03% -78% | |
| Revenue YoY (latest Q) | ◆ 22.04% | 16.30% | 20.76% | 19.01% | 19.01% +16% | |
| Net Income YoY (latest Q) | 59.77% | 25.22% | ◆ 82.18% | -7.12% | 25.22% +137% | |
| Profitability | ||||||
| EBITDA Margin | ◆ 22.09% | 20.34% | 20.51% | 12.05% | 20.34% +9% | |
| Net Income Margin | 11.09% | 10.41% | ◆ 12.27% | 7.60% | 10.41% +7% | |
| Return on Common Equity | 11.70% | 9.25% | 11.98% | ◆ 12.58% | 11.98% -2% | |
| Return on Capital Employed | ◆ 15.80% | 12.52% | 15.51% | 12.80% | 12.80% +23% | |
| Return on Assets | 7.71% | 5.99% | ◆ 9.57% | 6.92% | 6.92% +11% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 0.26× | 0.20× | ◆ 0.07× | 0.37× | 0.20× +30% | |
| Interest Coverage | 7.77× | 13.20× | ◆ 20.55× | 7.19× | 13.20× -41% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹5,366 Cr | ₹33,653 Cr | ₹9,646 Cr | ₹2,565 Cr | ₹9,646 Cr -44% | |
| Net Income | ₹595 Cr | ₹3,503 Cr | ₹1,184 Cr | ₹195 Cr | ₹1,184 Cr -50% | |
| Total Assets | ₹7,720 Cr | ₹58,502 Cr | ₹12,370 Cr | ₹2,815 Cr | ₹12,370 Cr -38% | |
| EPS | ₹24.47 | ₹60.34 | ₹44.98 | ₹21.36 | ₹44.98 -46% | |
| Book Value per Share | ₹205.21 | ₹652.25 | ₹375.41 | ₹169.74 | ₹375.41 -45% | |